Curaleaf Laboratories, one of the UK’s leading manufacturers and distributors of EU-GMP medical cannabis products and Herdade das Barrocas (HDB), a Portuguese cultivator known for its cannabis genetics and cultivation expertise, are pleased to announce a new manufacturing and supply partnership that will see HDB products reintroduced to healthcare professionals and patients across the United Kingdom (UK).
The agreement combines Herdade das Barrocas‘ cultivation capabilities in Portugal with Curaleaf Laboratories’ MHRA-approved manufacturing, quality assurance and distribution infrastructure in the UK. Together, the companies will deliver a range of cannabis-based medicinal products to UK prescribers and patients, strengthening supply chain resilience and expanding treatment options within the rapidly growing UK medical cannabis sector.
The partnership marks the return of Herdade das Barrocas products to the UK market, providing patients and healthcare professionals with renewed access to both cultivars that have previously been recognised market, as well as new strains cultivated and manufactured based on clinical need.
Under the agreement, cannabis flower cultivated by Herdade das Barrocas will be supplied to Curaleaf Laboratories for UK manufacturing, packaging and distribution, ensuring all products meet the quality and regulatory standards required for UK patient access.
Richard Hodgson, Managing Director at Curaleaf Laboratories: “We are delighted to partner with Herdade das Barrocas and support the return of their products to the UK market. This collaboration aligns with our commitment to support a broad portfolio of EU-GMP medical cannabis products while strengthening reliable supply into the UK healthcare system.”
Telmo Costa, Dir. Product, Markets & Operations at Herdade das Barrocas: “The UK remains one of Europe’s most important medical cannabis markets, and we are pleased to be working with Curaleaf Laboratories to reintroduce our products to UK patients. Curaleaf Laboratories’ manufacturing expertise, regulatory capabilities and established distribution network make them an ideal partner as we continue to expand our international presence.”
The partnership reflects both companies’ shared commitment to pharmaceutical quality standards, patient-centred innovation and sustainable growth within regulated medical cannabis markets.
As demand for medical cannabis continues to increase across the UK, the collaboration is expected to enhance product availability, improve supply continuity and provide healthcare professionals with additional options when prescribing cannabis-based medicinal products.
Initial product availability for healthcare professionals and patients as a result of this partnership is expected to begin from June 2026.
Healthcare professionals seeking information on prescribing or ordering can reach out to contact Curaleaf Laboratories at: info@curaleaflaboratories.co.uk.
